We evaluated efficacy and tolerance of hypofractionated stereotactic radiation treatment (hFSRT) in the management of intracranial meningiomas. Between December 2008 and June 2016, 126 patients with 136 intracranial meningiomas were treated with robotic hFSRT. hFSRT was performed as primary irradiation and as a salvage option for the local recurrence after prior radiotherapy. The median prescription dose was 25 Gy (12-40) with a median number of fractions of 5 (3-10). After a median follow-up of 20.3 months (range 1-77 months), the 24-months local control (LC) rate was 81% in the primary hFSRT group and 39% after hFSRT in the re-irradiation group (p=0.002). The clinical control rate of symptoms in the overall population was 95% (95% CI: 89-98%). Progression-free survival (PFS) in the overall population at 24 months was 70% (95% CI: 60%-79%). In the primary hFSRT group, PFS was significantly lower with the most hypofractionated schedules of 21-23 Gy in 3 fractions vs. 25-40 Gy in 5-10 fractions: 62% vs. 92% (p = 0.0006). The incidence of radionecrosis at 24 months was significantly lower in the primary hFSRT group, at 2% vs. 20% in the re-irradiation hFSRT group (p = 0.002).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135793 | PMC |
| http://dx.doi.org/10.1038/s41598-018-32124-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of hypofractionated stereotactic radiotherapy for primary optic nerve sheath meningioma.
Neurooncol Pract
April 2024
Department of Radiation Oncology, Hacettepe University School of Medicine, Ankara, Turkey.
Article Synopsis
- This study focuses on the effectiveness of hypofractionated stereotactic radiotherapy (HF-SRT) in treating rare optic nerve sheath meningiomas (ONSM), which can lead to vision problems.
- A total of 36 patients were treated, and results showed that 64% of tumors regressed and 89% achieved local control, with the majority of patients maintaining or improving their visual acuity over an average follow-up period of 106 months.
- The findings suggest that HF-SRT is a safe and effective treatment, with an emphasis on starting therapy before significant vision loss occurs, particularly noting that female patients had better visual outcomes.
Outcome after Radiotherapy for Vestibular Schwannomas (VS)-Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.
Cancers (Basel)
April 2022
Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied.
View Article and Find Full Text PDFImmunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
Neuro Oncol
October 2021
Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Biomedical Sciences "Mario Serio," Florence, Italy.
Background: To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SRT) including radiosurgery (RS) or hypofractionated SRT (HFSRT) for brain metastases (BM) from non-small cell lung cancer (NSCLC) in a multicentric retrospective study from AIRO (Italian Association of Radiotherapy and Clinical Oncology).
Methods: NSCLC patients with BM receiving SRT + IT and treated in 19 Italian centers were analyzed and compared with a control group of patients treated with exclusive SRT.
Results: One hundred patients treated with SRT + IT and 50 patients treated with SRT-alone were included.
Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study.
J Clin Transl Res
July 2020
Department of Radiation Oncology, Ramón y Cajal Hospital, Madrid, Spain.
Background: Radiosurgery is employed for the treatment of brain metastases. The aim of this study is to evaluate the efficacy and tolerability of single-dose radiosurgery (SRS) compared to hypofractionated stereotactic radiotherapy (hFSRT).
Materials And Methods: Between 2004 and 2018, we analyzed treatments of 97 patients with 135 brain metastases.
Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis.
Chin Clin Oncol
August 2020
Radiobiology laboratory, EA 3430, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, Strasbourg, France.
Background: To assess the risks of local and distant failure and overall survival time in patients treated with hypofractionated stereotactic radiotherapy (HFSRT) to the postoperative cavity for brain metastases (BMs) compared with patients treated with adjuvant whole-brain radiation therapy (WBRT).
Methods: Between July 2005 and February 2015, 196 non-randomized patients with 202 resected BMs were treated with post-operative WBRT or HFSRT at a single institution. The propensity score was included as a covariate to compare the interval to local failure, distant brain failure and overall survival time.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!